- Home
- LITM vs IGC Comparison
LITM vs IGC Comparison
Compare LITM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LITM | IGC |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 33.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LITM | IGC |
|---|---|---|
| Price | $3.24 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 702.9K | 626.1K |
| Earning Date | 10-31-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $0.25 |
| 52 Week High | $24.44 | $0.50 |
Technical Indicators
Market Signals| Indicator | LITM | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 30.14 |
| Support Level | $2.34 | $0.31 |
| Resistance Level | $2.80 | $0.34 |
| Average True Range (ATR) | 0.27 | 0.02 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 65.89 | 10.73 |
Price Performance
Historical ComparisonAbout LITM Snow Lake Resources Ltd.
Snow Lake Resources Ltd is a Canadian clean energy exploration company with a world-wide portfolio of clean energy mineral projects comprised of two uranium projects and two hard rock lithium projects. Its Projects include: The Black Lake Uranium Project, the Engo Valley Uranium Project, The Shatford Lake Project, and the Snow Lake Lithium Project.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.